<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243788</url>
  </required_header>
  <id_info>
    <org_study_id>SCO113162</org_study_id>
    <secondary_id>SCO113162</secondary_id>
    <nct_id>NCT01243788</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD</brief_title>
  <official_title>Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Province North Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armed Police Medical college Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Salmeterol/Fluticasone Propionate 50/500ug BID vs
      Ipratropium/Albuterol 36/206ug QID in Chinese patients with moderate-to-severe Chronic
      Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a 12-week, multicentre,randomized,open-label,active-controlled, paralleled-group
           study.

        -  Chinese patients aged ≥40 years with moderate-to-severe COPD are eligible for this
           study.

             1. If satisfying the entry criteria, patients enter an 8 to 14 day run-in period,and
                replace previous bronchodilators with inhaled or nebulized Salbutamol.

             2. Patients record daily severity ratings for daytime symptoms of shortness of breath,
                tiredness, activity limitation, frustration with symptoms, and night-time sleep
                symptoms on daily cards.

             3. Each symptom is rated using 0-100 visual analog scal (VAS). For overall assessment
                of daytime symptoms, a combined symptom score is obtained by adding VAS scores for
                shortness of breath, tiredness, activity limitation, frustration with symptoms.

             4. Patients are required to be symptomatic as demonstrated by a combined daytime
                symptom score of 120 on at least 4 of the 7 days prior to randomization.

             1. Eligible patients will be randomized (1:1) to the following 2 treatments for 12
                weeks.

                  1. Inhaled Salmeterol/Fluticasone propionate 50/500ug twice daily or inhaled
                     IB/ALB 36/206ug QID.

                  2. Salbutamol will be provided for relief of symptoms on an &quot;as required&quot; basis
                     during the whole 12 weeks.

             2. A Follow-up visit will be conducted 2 weeks after completion of treatment/early
                withdrawal to assess for any adverse effects after discontinuing study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pre-broncholidator FEV1</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in pre-broncholidator FEV1 at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-broncholidator FEV1</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in post-broncholidator FEV1 at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEF, inspiration capacity (IC) and Residual Volume (RV)</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in morning PEF, inspiration capacity (IC) and Residual Volume (RV)at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall daytime symptom score, reliever medication use,SGRQ and BODY index</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in overall daytime symptom score, reliever medication use,SGRQ and BODY index at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of symptom-free nights, sleep symptoms, nighttime awakenings due to respiratory symptoms</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in percent of symptom-free nights, sleep symptoms, nighttime awakenings due to respiratory symptoms at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers: serum Clara cell 16 (CC-16) protein and serum surfactant protein D (SPD)</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in biomarkers: serum Clara cell 16 (CC-16) protein and serum surfactant protein D (SPD) at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>participants with adverse events and COPD exacerbations</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>Change from Baseline in number of participants with adverse events and COPD exacerbations at 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Ipratropium/Albuterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ipratropium/Albuterol 36/206ug QID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/Fluticasone Propionate</intervention_name>
    <description>Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks</description>
    <arm_group_label>Ipratropium/Albuterol</arm_group_label>
    <other_name>Combivent</other_name>
    <other_name>Salbutamol Aerosol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese male or female outpatients aged 40 to 79 years, inclusive

          -  Patients with an established diagnosis of COPD, defined as GOLD guideline
             postbronchodilation FEV1/FVC ratio of &lt;70%, AND Postbronchodilation FEV1% predicted
             ranged from ≥25 to ≤70.

          -  A cigarette smoking history of 10 pack-years

          -  Use of oral theophylline, or any other inhaled medications other than LABA, LAMA, or
             ICS for≥30 days (e.g. SABA, SAMA)

          -  Patients who are able to use Accuhaler device and relief medication

          -  Patients willing to give informed consent to participate in the study and comply to
             study protocol

          -  Eligible female on child-bearing potentia

        Exclusion Criteria:

          -  Patients with concurrent respiratory disorders (e.g. asthma) other than COPD

          -  Patients with a requirement for regular or long term oxygen therapy (&gt;12h/d)

          -  Patients who used inhaled or oral steroids within 30 days of screening

          -  Patients who had a respiratory tract infection requiring antibiotics within 14 days of
             screening

          -  Patients with a moderate-to-severe COPD exacerbation within 30 days of screening

          -  Patients with any significant medical condition or disease that would place patients
             at risk or interfere with the study evaluation.

          -  Patients who used some inhibitory agents (e.g. b blockers) within 14 days of screening

          -  Female patients who is pregnant or may be pregnant in the study duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxue C BAI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yutong Y GU, Doctor</last_name>
    <phone>8621-64041990</phone>
    <phone_ext>2445</phone_ext>
    <email>gu.yutong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Anhui Medical College</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gengyun G Sun, Doctor</last_name>
      <phone>8613966673211</phone>
      <email>sungengyun@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingxiang Y Lin, Master</last_name>
      <phone>8613611370119</phone>
      <email>linyx666@yahoo.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bei B HE, Bachlor</last_name>
      <phone>8613910125933</phone>
      <email>puh3_hb@bjmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gguang Zhou Institute of Respiratory Disease</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingfang J Ma, Master</last_name>
      <phone>8620-83062880</phone>
      <email>majf1216@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun L Ma, Bachlor</last_name>
      <phone>8613837115111</phone>
      <email>malijun0401@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mao M Huang, Doctor</last_name>
      <phone>8613813886116</phone>
      <email>Hm6114@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital,</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuxing F Hui, Bachlor</last_name>
      <phone>8613358111977</phone>
      <email>HFX110705@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenyang Military General Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping P Chen, Doctor</last_name>
      <phone>8613309887193</phone>
      <email>HXNK2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutong Y GU, doctor</last_name>
      <phone>8621-64041990</phone>
      <phone_ext>2425</phone_ext>
      <email>gu.yutong@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuqiang F Wen, Doctor</last_name>
      <phone>8613628040336</phone>
      <email>wenfuqiang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Xinqiao Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>430007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changzheng C Wang, Doctor</last_name>
      <phone>8613983815706</phone>
      <email>czwang@netease.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chunxue BAI</name_title>
    <organization>Zhongshan Hospital</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Seretide</keyword>
  <keyword>Combivent</keyword>
  <keyword>effect and safety</keyword>
  <keyword>Twelve weeks</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

